#ATE22: The European CGT landscape in Tweets#ATE22: The European CGT landscape in Tweets

Before we consider and celebrate #CGT in a #EuropeanMarket at out #AdvancedTherapiesEurope event next month, take a look at this handy infographic with 5 Disruptive Strategies for Market & Patient Access in Europe. Do you agree with them?

Take a look 👇https://t.co/EvBfHAFRvs

— Phacilitate (@Phacilitate) July 13, 2022

Honoured to be here, thank you all for a great discussion. CAR-Ts are expensive but they work. Ten years from now the former will be less true and the latter even more so…

— Anthony Davies (@ADaviesDHCG) August 31, 2022

Anthony Davies speaking about the challenges and opportunities within the UK & EU CGT landscape – ‘Europe is complex but there may be some advantage to that complexity’ #AdvancedTherapiesEurope

— BioProcess Insider (@BioProInsider) August 31, 2022

‘Why is CAR-T treatment so expensive?’ Tom Whitehead replies ‘because it’s worth it’ #AdvancedTherapiesEurope

— BioProcess Insider (@BioProInsider) August 31, 2022

We were excited to present an update on our @UKRI_News supported digitisation project with our partner Stuart Curbishley from the @unibirmingham at the @Phacilitate Europe last week. Amazing discussion and presentations from the industry experts in the panel session #ATMPs pic.twitter.com/qBl5brtLMg

— Autolomous (@autolomous) September 5, 2022

Stuart Curbishley: ‘Most drug discoveries tend to happen inside global pharmaceutical companies but in the CGT space, most come out of academic institutions’ #AdvancedTherapiesEurope

— BioProcess Insider (@BioProInsider) September 1, 2022

What does the Europe CGT landscape look like in comparison to North America – and what can either side of the pond learn? Kinnari Patel, @RocketPharma, Miguel Forte, @BoneTherapeutic in conversation with @ADaviesDHCG, @darkhorsecagt #advancedtherapiesEurope #ate22 #ate2022 pic.twitter.com/UPkvsc4UCw

— Ryan Leahy (@RySciComms) August 31, 2022

Miguel Forte: ‘there’s similarities between Europe and the US about the strength of science. There is a more fluid and aggressive environment in US than Europe’ #AdvancedTherapiesEurope

— BioProcess Insider (@BioProInsider) August 31, 2022

@Phacilitate‘s #AdvancedTherapies Europe. Key industry milestones in the last 10 years: 👉 “Achieving scale-up and 95% manufacturing success rate” – @Novartis 👉 “Achieving 82% CR in early trial”- @darkhorsecagt(2/3)

— Autolomous (@autolomous) September 1, 2022

Karin Blumer @Novartis/@NovartisGene is running a session on patient engagement and the importance of involving the patient in the entire CGT process.#ATE2022 #ATE22 #advancedtherapieseurope #celltherapy #genetherapy #patientengagement #patientadvocacy @Phacilitate pic.twitter.com/3qgubOtUPl

— Ryan Leahy (@RySciComms) August 31, 2022

Many calls at @Phacilitate #ate2022 for collaboration to overcome many of the challenges in cell therapy. Make sure to include academia and #patients e.g. @GoCARTcoalition . Also not to reinvent the wheel e.g #traceability @ISBT128 https://t.co/301B02QMz0

— Eoin McGrath (@EoinMcG_Work) August 31, 2022

Jenny Prange says that it is difficult to get additional funding for the next logical steps as companies are often asked for efficiency data in Europe, which isn’t what Phase I trials are for #AdvancedTherapiesEurope

— BioProcess Insider (@BioProInsider) August 31, 2022

Elsa Abranches: ‘I think we need to diversify and rely on the expertise that are around us and use ourselves to progress faster’ #AdvancedTherapiesEurope

— BioProcess Insider (@BioProInsider) September 1, 2022

Thanks to all who attended the fantastic talk today by Dr Allison Blair, who highlighted how NHSBT manufacture everything from plasmids to red blood cells! We are all excited to hear how the RESTORE trial progresses👩‍🔬👨‍🔬

Thanks @Phacilitate for organising #AdvancedTherapiesEurope pic.twitter.com/kaNDH455Fu

— NHSBT Cellular and Molecular Therapies (@NHSBT_CMT) September 1, 2022